# Curis, Inc. (CRIS)

> Source: Nexqual · https://nexqual.com/CRIS · data as of 2026-10-23 14:40 UTC · cite as "Nexqual, Curis, Inc. (CRIS), nexqual.com/CRIS" · informational, not investment advice.

**Price:** USD 0.4 (-0.44% today) · US market open, as of October 23, 2026 at 14:40 UTC; quotes may be delayed. Prev close 0.4 · day 0.39–0.42 · 52w 0.33–33.6 · market cap $978K · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $4.3M, net income -$21.2M (-490.3% margin) (SEC filings).
- 1 of 80 tracked superinvestors hold CRIS (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Total return with dividends: 1Y -98.8% vs S&P 500 +14.8%; 5Y -100.0% vs S&P 500 +77.5%.
- Next earnings: 2026-11-05, EPS estimate USD -2.01, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M | $4.3M |
| Operating income | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$5.7M | -$8.8M |
| Net income | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M | -$21.2M |
| EPS (diluted) | $10.00 | -$242.80 | -$179.20 | -$137.60 | -$11.60 | — |
| Free cash flow | -$37.6M | -$54.8M | -$38.4M | — | — | — |
| Operating margin | -395.0% | -521.7% | -482.2% | -408.3% | -60.5% | -203.2% |
| Net margin | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% | -490.3% |
| Revenue growth | -1.7% | -4.6% | -1.4% | +8.8% | -13.4% | — |
| Cash + short-term investments | $140M | $85.6M | $56.3M | $20.0M | $5.1M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.2x · P/B 0.2x · Earnings yield -2163.88%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold CRIS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | <0.01% | $6K | Unchanged |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-17 | HC Wainwright & Co. | Reiterated | Buy | $43 |
| 2026-07-24 | HC Wainwright & Co. | Target raised | Buy | $17 → $43 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -98.8% | -100.0% |
| S&P 500 (SPY) | +14.8% | +77.5% |
| Per year | -98.8% | -82.7% |
| Volatility (annualized) | 129.4% | 103.2% |
| Max drawdown | -98.8% (Oct 2025→Oct 2026) | -100.0% (Oct 2021→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.44 -1.61% · LGND (Ligand Pharmaceuticals Incorpor) USD 307.52 -0.10% · IOVA (Iovance Biotherapeutics, Inc.) USD 13.78 -2.55% · PRAX (Praxis Precision Medicines, Inc) USD 254.29 -1.79% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.85 -2.43% · ABVX (Abivax SA) USD 87.77 -2.73%

## More
Full page: https://nexqual.com/CRIS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CRIS's own 10-K filed 2026-03-24 (https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/cris-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Aurigene Discovery Technologies | "We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948)." |
| Partner | Genentech | "In 2003, we entered into a Collaborative Research, Development and License Agreement, dated as of June 11, 2003, with Genentech, Inc. (as amended by the First Amendment to the Collaborative Research, Development and Lice…" |
| Partner | Curis Royalty | "In connection with such transaction, we transferred to Curis Royalty all rights to Curis Technology, Inventions and Joint Patents (each as defined in the Genentech License Agreement) and assigned our rights, duties and o…" |

## Customer concentration

Period ended 2025-12-31: 100%, 100% of revenue from unnamed direct customers (10-K, filed 2026-03-24).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-2.01 | $-6.73 | -70.1% | $0 | 2 |
| Next quarter (ends 2026-12-31) | $-1.63 | $-6.53 | -75.1% | $0 | 2 |
| Current fiscal year (ends 2026-12-31) | $-23.78 | $-31.20 | -23.8% | $0 | 3 |
| Next fiscal year (ends 2027-12-31) | $-6.01 | $-23.73 | -74.7% | $9.3M | 3 |